Lanza F L, Rack M F, Wagner G S, Balm T K
Dig Dis Sci. 1985 Jun;30(6):509-12. doi: 10.1007/BF01320255.
When administered on a chronic high-dosage regimen, enteric-coated aspirin granules produced significantly less gastric damage than plain aspirin or aspirin-antacid combinations. Clinically meaningful damage occurred in all subjects receiving plain aspirin, 93% of those receiving aspirin-antacid combination and only 27% and 20% of those receiving enteric-coated aspirin granules qid and bid, respectively. All three aspirin formulations were taken as 1 g qid (4 g/day) and an additional group received enteric granules administered as 2 g bid (4 g/day). Gastric damage was assessed by means of endoscopy carried out after seven days of treatment. Enteric granules are equally safe when administered on a bid or qid regimen (at same total daily dosage) and, in a bid regimen, should provide a compliance advantage for patients on high-dose therapy for diseases such as rheumatoid arthritis.
当以慢性高剂量方案给药时，肠溶包衣阿司匹林颗粒造成的胃损伤明显少于普通阿司匹林或阿司匹林与抗酸剂的组合。所有服用普通阿司匹林的受试者均出现了具有临床意义的损伤，服用阿司匹林与抗酸剂组合的受试者中这一比例为93%，而每日四次和每日两次服用肠溶包衣阿司匹林颗粒的受试者中，这一比例分别仅为27%和20%。所有三种阿司匹林制剂均按每日四次、每次1克（每日4克）服用，另有一组接受每日两次、每次2克（每日4克）的肠溶颗粒。治疗七天后通过内镜检查评估胃损伤情况。肠溶颗粒在每日两次或每日四次给药方案（每日总剂量相同）下同样安全，并且在每日两次给药方案中，对于类风湿关节炎等疾病接受高剂量治疗的患者而言，应具有更好的依从性优势。
